GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaResearch Co Ltd (XKRX:214450) » Definitions » Debt-to-Revenue

PharmaResearch Co (XKRX:214450) Debt-to-Revenue : 0.11 (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is PharmaResearch Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaResearch Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₩33,127 Mil. PharmaResearch Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was ₩1,925 Mil. PharmaResearch Co's annualized Revenue for the quarter that ended in Jun. 2024 was ₩332,426 Mil. PharmaResearch Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.11.


PharmaResearch Co Debt-to-Revenue Historical Data

The historical data trend for PharmaResearch Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaResearch Co Debt-to-Revenue Chart

PharmaResearch Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.21 0.42 0.34 0.13

PharmaResearch Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.18 0.12 0.14 0.11

Competitive Comparison of PharmaResearch Co's Debt-to-Revenue

For the Biotechnology subindustry, PharmaResearch Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaResearch Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaResearch Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where PharmaResearch Co's Debt-to-Revenue falls into.



PharmaResearch Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

PharmaResearch Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(33006.061 + 523.189) / 261010.911
=0.13

PharmaResearch Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(33126.565 + 1925.369) / 332426.328
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jun. 2024) Revenue data.


PharmaResearch Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of PharmaResearch Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaResearch Co Business Description

Traded in Other Exchanges
N/A
Address
74 Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Seongnam, KOR, 463-400
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.

PharmaResearch Co Headlines

No Headlines